On Wednesday, bharat biotech denied reports of any wrongdoing in the Covaxin procurement deal in Brazil and said it followed a common, widely accepted, and established process that included an advance payment.
“We wish to dispel any notion or implication of any wrongdoing whatsoever, as all these are affiliate companies found/acquired and operated by Dr Krishna Ella. More than 3,000 personnel are employed in 6 cities across all these organizations,” Bharat Biotech said in a statement.
The pharma company’s response comes amid reports that Brazil is suspending its $324 million deal to procure indigenously developed Covaxin due to suspected irregularities.
Discussion about this post